TrialInternational journal of cancer2021

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.

Manuel Dómine Gómez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.